INFLUENZA VACCINES MARKET ANALYSIS

Influenza Vaccines Market, By Vaccine Type (Inactivated, Live Attenuated), By Valency (Quadrivalent, Trivalent), By Route of Administration (Injection, Nasal Spray), By Age Group (Paediatrics, Adults), By Technology (Egg-Based Flu Vaccines, Cell Culture-Based Flu Vaccines, Recombinant Flu Vaccines), By Distribution Channel (Public, Private), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Mar 2024
Code : CMI1705
Pages :197
Formats :
Excel and PDF
Industry : Biotechnology

Key Developments

On March 06, 2024, CSL Seqirus, a global leader in public health protection, announced that it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 season in the U.S., based on the trivalent strains recommended by the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC).
On February 15, 2024 Osivax, a biopharmaceutical company, stated that the first person had been vaccinated in its new Phase 1 study (NCT06128382) of OVX033, a broad-spectrum sarbecovirus vaccine candidate. The single-center trial is a randomized, double-blind, placebo-controlled Phase 1 clinical investigation to evaluate the safety and immunogenicity of OVX033 at three dose levels (100 µg, 250 µg, and 500 µg).
In October 2023, Pfizer Inc., a pharmaceutical and biotechnology company, and BioNTech SE, a biotechnology company, announced positive topline results from a Phase 1/2 study (NCT05596734) that assessed the safety, tolerability, and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 in healthy adults aged 18 to 64.
In October 2023, AstraZeneca, a science-led biopharmaceutical company, announced that the U.S. FDA had accepted its Supplemental Biologics License Application (sBLA) for the approval of a self- or caregiver-administered option for FluMist Quadrivalent, a needleless nasal spray. If approved, FluMist will be the first flu vaccine that may be self-administered by qualified patients or caregivers, providing another way to get vaccinated against influenza.